Reach Us +44-1647-403003
Endocan as a Biomarker of Endothelial Dysfunction in Cancer | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Endocan as a Biomarker of Endothelial Dysfunction in Cancer

Sarrazin Stéphane1, Maurage Claude-Alain2, Delmas Dominique3, Lassalle Philippe4and Delehedde Maryse4,5*

1Department of Cellular and Molecular Medicine, University of California, La Jolla, USA

2Centre de Pathologie Biologie, CHRU de Lille, F-59000, Lille, France

3Futurs Health Products, F-94140 Alfortville, France

4Institut Pasteur de Lille, Univ Lille Nord de France, Inserm U1019, Center for Infection and Immunity of Lille, F-59019, Lille, France

5Lunginnov, Institut Pasteur de Lille, F-59019, Lille, France

*Corresponding Author:
Dr. Delehedde Maryse
Lunginnov, Institut Pasteurde Lille
1 rue du professeur Calmette, 59000 Lille, France
Tel: (33) 680223199,
E-mail: [email protected]

Received Date:March 03, 2010; Accepted Date: April 01, 2010; Published Date: April 01, 2010

Citation: Sarrazin S, Maurage CA, Delmas D, Lassalle P, Delehedde M (2010) Endocan as a Biomarker of Endothelial Dysfunction in Cancer. J Cancer Sci Ther 2: 047-052. doi: 10.4172/1948-5956.1000022

Copyright: © 2010 Sarrazin S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Endocan also called endothelial cell-specific-molecule-1 is a product of endothelial cells, highly regulated by vascular endothelial growth factor and expressed during the switch between dormant to fast-growing angiogenic tumors. No other molecule is currently known to be a read out of endothelial activation and dysfunction in tumor progression. We here reviewed the present knowledge about endocan that present clinical value as a tissue- and blood- based prognostic and potentially as a companion biomarker in cancer. By immunohistochemistry endocan was shown to be overexpressed into endothelial cells of small and large vessels in lung, kidney and brain tumors. High endocan serum levels were shown to be significantly correlated with the presence of metastasis and with limited survival in kidney and lung cancers. Moreover, endocan release by endothelial cells was in vitro modulated by addition of anti-angiogenic compounds. At a time where biomarkers are hugely needed to improve anti-angiogenic targeted treatments, endocan could be a pertinent biomarker to select patients and/or to clinically monitor the efficacy of cancer drugs. Through its awaited functional applications, endocan appears today as a promising biomarker to access to personalized medicine and to optimize therapy cost / benefit ratio.


Share This Page